MECOM

Across TCGA pan-cancer cohorts, MECOM mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MECOM data layer compared with 22 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MECOM mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MECOM expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

CCRCC, GBM, and LUAD are the cancer types where MECOM mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.866	0.607	.001	43	view →
GBM	OS	Median	All	1.000	0.117	.024	21	view →
LUAD	OS	Quartile	II,III,IV	1.000	0.314	.017	8	view →
LSCC	OS	Median	All	0.912	0.849	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MECOM–CCRCC (DFS)

Open the CCRCC breakdown →